MCCC1

MCCC1 encodes the biotin-containing alpha-subunit of mitochondrial 3-methylcrotonyl-CoA carboxylase (MCC), a biotin-dependent enzyme that catalyzes a key step in leucine catabolism; the protein carries a mitochondrial signal peptide together with biotin carboxylase and biotin-carrier domains, and is most abundant in mitochondria-rich organs (PMID:11406611, PMID:11401427). Loss-of-function missense and truncating mutations in conserved residues abolish carboxylase activity in patient fibroblasts, causing 3-methylcrotonyl-CoA carboxylase deficiency (PMID:11406611, PMID:11401427, PMID:14680978). Beyond catalysis, MCCC1 has emerging roles in cellular signaling: it binds the pro-apoptotic protein Bad and stabilizes it, such that MCCC1 depletion shortens Bad half-life, lowers Bax, raises anti-apoptotic Bcl-xL and Mcl-1, and induces mitochondrial dysfunction and multidrug resistance (PMID:37805164). Its catabolic activity is also a target of regulatory lncRNAs: lncBADR binds MCCC1 to inhibit branched-chain amino acid degradation, driving BCAA accumulation that activates mTOR-Stat1 signaling and IFN-γ secretion in pathogenic T cells, while AABR07005593.1 binds MCCC1 to promote NF-κB activation and IL-6 induction (PMID:34619471, PMID:41013574). A Parkinson's disease-associated intronic variant, rs12637471, causally elevates MCCC1 expression in dopaminergic neurons, as shown in isogenic CRISPR-edited iPSC lines (PMID:40216992).

1. 2001 High

   Establishing the molecular identity of MCCC1 answered what gene product underlies one branch of leucine catabolism and what its disease relevance is, defining it as the biotin-dependent alpha-subunit of MCC whose mutation abolishes enzyme activity.

   Evidence cDNA cloning, genomic sequencing, chromosomal mapping, and patient mutation identification with fibroblast enzyme assays; replicated tissue expression analysis

   PMID:11401427 PMID:11406611

   Open questions at the time

   • No structural data on the human holoenzyme
   • Stoichiometry and assembly with the beta-subunit not resolved in these studies
2. 2003 Medium

   Functional complementation showed that conserved-residue missense mutations are directly causal for loss of carboxylase activity, linking specific structural positions to catalytic competence.

   Evidence Transient transfection of patient-derived deficient fibroblasts with enzyme activity readout plus homology modelling onto E. coli acetyl-CoA carboxylase

   PMID:14680978

   Open questions at the time

   • Structural inference is computational, not a human crystal structure
   • Does not address regulation of the enzyme in vivo
3. 2021 Medium

   Identifying MCCC1 as a direct binding partner of lncRNA AABR07005593.1 extended its role beyond metabolism into inflammatory signaling.

   Evidence ChIRP-MS with western blot validation and RNAi pathway placement in PM2.5-stimulated alveolar macrophages

   PMID:34619471

   Open questions at the time

   • Single lab without reciprocal validation
   • Mechanism by which MCCC1 binding drives NF-κB activation is undefined
4. 2023 Medium

   The MCCC1-Bad interaction connected the enzyme to apoptotic regulation, showing it stabilizes a pro-apoptotic protein and that its loss reprograms the Bcl-2 family balance toward survival and drug resistance.

   Evidence Reciprocal Co-IP, structural simulation, Bad half-life assay, apoptosis assays, and xenograft model in multiple myeloma cells

   PMID:37805164

   Open questions at the time

   • Single lab
   • Molecular basis of MCCC1-mediated Bad stabilization not defined
   • Whether catalytic activity is required for the apoptotic role is untested
5. 2024 Medium

   Chemical-probe target identification revealed MCCC1 as a direct small-molecule binding target of corosolic acid, linking the enzyme to insulin resistance signaling.

   Evidence CA-biotin affinity pull-down with quantitative proteomics, in vitro binding validation, and diabetic mouse model

   PMID:39731787

   Open questions at the time

   • Single lab
   • Binding site and effect on enzymatic activity unresolved
   • Causal contribution of MCCC1 to the insulin phenotype not isolated genetically
6. 2025 Medium

   Two studies established MCCC1 as a regulated node: lncBADR binding inhibits BCAA degradation to drive mTOR-Stat1/IFN-γ in pathogenic T cells, and a PD-risk variant causally elevates MCCC1 expression in dopaminergic neurons.

   Evidence T cell-specific lncBADR knockout EAE model with metabolic rescue; CRISPR/Cas9 isogenic iPSC-derived dopaminergic neurons with postmortem brain and GTEx eQTL corroboration

   PMID:40216992 PMID:41013574

   Open questions at the time

   • Functional consequence of elevated MCCC1 in dopaminergic neurons for PD pathology unknown
   • lncBADR mechanism of inhibiting MCCC1 catalysis not defined

• How MCCC1's canonical carboxylase activity is mechanistically coupled to its non-metabolic roles in apoptosis, inflammation, and neuronal disease risk remains unresolved.
• No human holoenzyme structure
• Unclear whether enzymatic and signaling functions are separable
• Causal link between MCCC1 dosage and Parkinson's disease neurodegeneration not established